explore -WSS

explore

author：leisure time 2025-09-29 20:17:39 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

leisure time

WSS

An interview with Robert F. Kennedy Jr. on vaccines

3 hurdles to bringing medical devices to the U.S. market

Cloning humans is technically possible. It's curious no one has tried

Listen: Racing for gene therapy & a pioneering approval

Trump cancels press conference intended to dispute Georgia election interference charges

Why drug prescriptions should include diagnoses

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Continuity nursing helped my family in our darkest PICU moments

#NeedHerScience: shining a light on gender disparities in medicine

Cancer drug shortages should be causing more outrage

The science behind Janet Jackson's pregnancy at 49

The high cost of giving birth even with insurance

FDA approves first treatment for ultra

Virginia high school admissions case could be legal follow

The pain doctors face in trying to build their families

Guidelines to prevent youth baseball injuries need more muscle

With FDA staff opposed to Sarepta therapy, top official intervened

focus

Donald Trump's relentless attacks on special counsel Jack Smith

Beware the threat of staffing cuts at the CDC

Congress must give Medicare recipients genetic counseling access

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Weight bias in eating disorder treatment complicated by new weight loss drugs

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

leisure time

focus

leisure time

hotspot